Physician profile
Shailesh Shetty
NPI 1750343620
$7,295.45
in general payments reported to CMS, 2019-2025
31 companies · $717 in 2025
The $717 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $1,535 · 2021: $510 · 2022: $764 · 2023: $674 · 2024: $1,545 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,507 · Travel and Lodging: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.64 |
| Travel and Lodging | $429.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,379.88 | 2019-2024 | Sapien 3 Ultra Resilia |
| Amgen INC. | $1,198.33 | 2019-2025 | Repatha, Repatha |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $760.42 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $538.03 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $447.74 | 2021-2025 | Verquvo, Capvaxive |
| Intuitive Surgical, INC. | $382.01 | 2024 | |
| Medtronic, INC. | $374.40 | 2023-2025 | Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $297.87 | 2022-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $287.92 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $257.44 | 2019-2025 | |
| Abbott Laboratories | $248.29 | 2019-2024 | Mitraclip |
| Baxter Healthcare | $166.12 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Biotronik INC. | $154.34 | 2023-2025 | Biomonitor, Selectra, Renamic Neo |
| Pfizer INC. | $111.89 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.51 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $65.97 | 2020-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $63.60 | 2021-2023 | Arcalyst |
| Novo Nordisk INC | $61.29 | 2024-2025 | |
| Abiomed | $54.54 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $49.02 | 2022-2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $46.02 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $44.34 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $43.96 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $31.76 | 2024 | Assure Wcd |
| Tactile Systems Technology INC | $29.15 | 2021 | |
| Reflow Medical INC | $28.22 | 2025 | |
| Medtronic Vascular, INC. | $25.10 | 2020 | |
| Shockwave Medical, INC | $24.67 | 2022 | |
| Chiesi USA, INC. | $22.24 | 2022 | |
| Angiodynamics, INC. | $18.96 | 2025 | Auryon Laser System 100-120 Vac |
| Boston Scientific Corporation | $14.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailesh Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.